Dr. Frances A. Collichio, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 131
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Rochester School of Medicine and Dentistry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Hematology & Oncology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Rex Hospital Raleigh, NC
- Unc Health Nash Rocky Mount, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 689
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 173 | 67 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 107 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 85 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 20 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 19 | 15 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chapel Hill, NC | 37 |
| Mektovi (binimetinib) | 27 |
| Braftovi (encorafenib) | 26 |
| Prochlorperazine Maleate Other prescribers in Chapel Hill, NC | 24 |
| Hydrocortisone Other prescribers in Chapel Hill, NC | 22 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Chapel Hill, NC | 19 |
| Amlodipine Besylate Other prescribers in Chapel Hill, NC | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,452 in research payments for these studies, mostly to the institutions running them.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.